LabCorp to Offer Ipsogen's JAK2 Leukemia Assay in US via CLIA Labs | GenomeWeb
NEW YORK (GenomeWeb News) - LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said today.
 
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.